ReviewDermatology and therapy2026

Real-World Benefit of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Findings from a Systematic Literature Review and Meta-Analysis.

Scott Gottlieb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.